GSE176230
HAMSAB supplement enhances SCFA production associated with microbiota and immune modulation in type 1 diabetes
Purpose: Short chain fatty acids (SCFAs) produced by the gut microbiota have dual beneficial anti-inflammatory and anti-dysbiotic effects associated with the prevention of type 1 diabetes (T1D) in mice. We have conducted a single-arm trial of a dietary supplement (HAMSAB), to determine the effects of increasing SCFA delivery  in adults with long-standing T1D. Particularly, we examined blood transcriptome in these patients using RNA-seq. Methods: Blood was collected from patients at baseline and after 6 weeks of HAMSAB supplementation. Whole blood was collected directly into Paxgene or Tempus tubes containing RNA stabilisers and extracted according to the manufacturer's protocol. Next-gene sequencing of patients' whole blood transcriptome was performed by Genewiz using Illumina NovaSeq platform obtaining sequence depth of 50 million reads/sample. Results: Several signalling pathways including fatty acid oxidation were found to be regulated by HAMSAB Overall design: To compare mRNA profiles in whole blood from T1D patients at baseline and after HAMSAB supplementation